Jill E. Anderson

Partner

Contact Me

T(212) 554-7836

F(917) 206-4377

Jill E. Anderson is a partner in the Healthcare and Privacy & CyberSecurity practice groups at Moses & Singer. She counsels emerging to late stage biotechnology companies, medical device companies, patient advocacy groups, research foundations and institutes, biorepositories,  research consortia and academic medical centers on regulatory and compliance issues related to product development and the privacy and security of data.

Jill has significant experience advising clients how to structure and implement research organizations, models and strategic collaborations. She has drafted and negotiated hundreds of complex research agreements and plays a crucial role in identifying & mitigating regulatory and compliance risks related to research and development. She counsels clients on cutting edge issues involving clinical and translational research including personalized medicine, therapeutics, diagnostics, genomics, proteomics, cell regeneration, biorepositories, research misconduct, fraud and abuse issues, anti-kickback laws and clinical trial disclosure and registration requirements.

Jill also provides strategic advice to a variety of health care clients on complex privacy and security issues related to data management including HIPAA and HITECH; data mining, electronic health record development and implementation; deployment of electronic health record systems, affiliations and joint ventures between healthcare providers and vendors who service providers. She counsels clients on how to preserve, protect and recover electronic research data as well as how to address potential and actual data security breaches and vulnerabilities.

Jill was formerly an attorney with Dana-Farber Cancer Institute and Partners Healthcare System (founded by Massachusetts General Hospital and Brigham and Women's Hospital), where she focused on regulatory and compliance issues related to clinical research.

Law School Activities/Honors
  • Widener Law Symposium Journal
  • Member, Phi Delta Phi
Presentations [View All]
  • "Regulatory Strategy and Revenue Generation for Life Sciences Startups," Bio & Health Tech Entrepreneurship Lab, NYC Economic Development Corp., January 2014
  • Speaker, "Contracts and Legal Documents," Bio & Health Tech Entrepreneurship Lab NYC, February 2013
  • Strafford Webinar, "Clinical Trials Compliance: Latest Regulatory and Enforcement Developments," October, 2012
  • Fordham University School of Law and Moses & Singer CLE Program, "Recent Developments in U.S. Law: Privacy and Information Technology," July 2012
  • Drug Information Association Annual Meeting, "Best Practices in Clinical Trials," June 2010
  • New England Healthcare Internal Auditors Association, "Clinical Trials and Research Compliance," May 2008
  • Massachusetts General Hospital Institute of Health Professions, Graduate Program in Clinical Investigations, Guest Lecturer, "Law and Health Policy in Clinical Research," November 2007
  • Healthcare Financial Management Association, "Regulatory Issues in Clinical Research," November 2007
Professional Affiliations
  • American Health Lawyers Association, Life Sciences and Academic Medical Centers/Teaching Hospitals Practice Groups
  • Boston Bar Association, Health Law Section
  • Women Entrepreneurs in Science and Technology
  • Harvard Biotechnology Club
  • New York Biotechnology Association

Representative Matters

  • Designed complex privacy program for national non-profit disease-specific patient advocacy group. 
  • Structured and implemented GLP-compliant biobank that integrates patient tissue samples with corresponding laboratory and clinical data.
  • Counseled client in creating the first clinical network that brought together leading academic centers solely dedicated to Phase I and Phase II clinical trials.
  • Represented client in launching landmark personalized medicine study to focus on disease progression and response to treatment based on patients’ genomic or molecular profiles.
  • Structured and negotiated a strategic joint venture which created a research and development consortium comprised of pharmaceutical/biotechnology companies and research institutions.
  • Developed and implemented privacy policies and procedures for international medical device company.
Biography

Jill E. Anderson is a partner in the Healthcare and Privacy & CyberSecurity practice groups at Moses & Singer. She counsels emerging to late stage biotechnology companies, medical device companies, patient advocacy groups, research foundations and institutes, biorepositories,  research consortia and academic medical centers on regulatory and compliance issues related to product development and the privacy and security of data.

Jill has significant experience advising clients how to structure and implement research organizations, models and strategic collaborations. She has drafted and negotiated hundreds of complex research agreements and plays a crucial role in identifying & mitigating regulatory and compliance risks related to research and development. She counsels clients on cutting edge issues involving clinical and translational research including personalized medicine, therapeutics, diagnostics, genomics, proteomics, cell regeneration, biorepositories, research misconduct, fraud and abuse issues, anti-kickback laws and clinical trial disclosure and registration requirements.

Jill also provides strategic advice to a variety of health care clients on complex privacy and security issues related to data management including HIPAA and HITECH; data mining, electronic health record development and implementation; deployment of electronic health record systems, affiliations and joint ventures between healthcare providers and vendors who service providers. She counsels clients on how to preserve, protect and recover electronic research data as well as how to address potential and actual data security breaches and vulnerabilities.

Jill was formerly an attorney with Dana-Farber Cancer Institute and Partners Healthcare System (founded by Massachusetts General Hospital and Brigham and Women's Hospital), where she focused on regulatory and compliance issues related to clinical research.

Law School Activities/Honors
  • Widener Law Symposium Journal
  • Member, Phi Delta Phi
Presentations [View All]
  • "Regulatory Strategy and Revenue Generation for Life Sciences Startups," Bio & Health Tech Entrepreneurship Lab, NYC Economic Development Corp., January 2014
  • Speaker, "Contracts and Legal Documents," Bio & Health Tech Entrepreneurship Lab NYC, February 2013
  • Strafford Webinar, "Clinical Trials Compliance: Latest Regulatory and Enforcement Developments," October, 2012
  • Fordham University School of Law and Moses & Singer CLE Program, "Recent Developments in U.S. Law: Privacy and Information Technology," July 2012
  • Drug Information Association Annual Meeting, "Best Practices in Clinical Trials," June 2010
  • New England Healthcare Internal Auditors Association, "Clinical Trials and Research Compliance," May 2008
  • Massachusetts General Hospital Institute of Health Professions, Graduate Program in Clinical Investigations, Guest Lecturer, "Law and Health Policy in Clinical Research," November 2007
  • Healthcare Financial Management Association, "Regulatory Issues in Clinical Research," November 2007
Professional Affiliations
  • American Health Lawyers Association, Life Sciences and Academic Medical Centers/Teaching Hospitals Practice Groups
  • Boston Bar Association, Health Law Section
  • Women Entrepreneurs in Science and Technology
  • Harvard Biotechnology Club
  • New York Biotechnology Association
Education
  • Widener University School of Law (J.D.)
  • Rutgers University (B.S.)
Bar/Court Admissions
  • Massachusetts
  • Pennsylvania
  • New York
Representative Matters
  • Designed complex privacy program for national non-profit disease-specific patient advocacy group. 
  • Structured and implemented GLP-compliant biobank that integrates patient tissue samples with corresponding laboratory and clinical data.
  • Counseled client in creating the first clinical network that brought together leading academic centers solely dedicated to Phase I and Phase II clinical trials.
  • Represented client in launching landmark personalized medicine study to focus on disease progression and response to treatment based on patients’ genomic or molecular profiles.
  • Structured and negotiated a strategic joint venture which created a research and development consortium comprised of pharmaceutical/biotechnology companies and research institutions.
  • Developed and implemented privacy policies and procedures for international medical device company.